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Abstract
Objective: To compare surgical outcomes between matched central hepatectomy (CH) and extended
hepatectomy (EH) groups.
Background: Surgical choices for centrally located liver tumours are limited. The traditional EH
harbours substantial risks, whereas CH is an alternative parenchymal-sparing resection that may
improve peri-operative morbidity.
Methods: A review of 4661 liver resections at a single institution was performed. The cases (CH) were
matched in a 1:1 ratio with EH controls.
Results: The CH group was matched for demographic, tumour and laboratory factors with either right
EH or combined (right/left) EH groups (n = 63 per group). Colorectal liver metastases were the most
common diagnosis occurring in 70% of the patients. Higher intra-operative blood loss was observed in
the right EH(P = 0.01) and combined EH groups (P < 0.01) compared with the CH group. There was a
trend towards lower 90-day morbidity in the CH group (43%) compared with the right EH(59%,
P = 0.1) and combined EH groups (56%, P = 0.2). The length of hospital stay was significantly longer
in the control groups (P < 0.01 for both). The control groups had significantly higher post-operative
bilirubin and International Normalized Ratio (INR) levels compared with the CH group. A post-operative
bilirubin higher than 4 mg/dl was observed in 2% of the CH group compared with 39% of the right EH
group (P < 0.01) and 52% of the combined EH group (P < 0.01). No differences in the rates of bile
leak/biloma, post-hepatectomy liver failure or 90-day mortality were found.
Conclusions: CH, as compared with EH, was safe and associated with a shorter hospital stay and
less post-operative liver dysfunction. CH should be considered in patients with centrally located
tumours amenable to such a resection.
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Introduction
A hepatic resection is an effective treatment option for
selected patients with malignant liver tumours.1,2 Centrally
located tumours of the liver involving segments 4, 5 and 8
may require extended resections (right or left hepatectomy
extended to the contralateral liver) because of their proxim-
ity to major central vascular and biliary structures.3,4 As it is
well documented that the morbidity of a liver resection is
related to the extent of resection, such extended resections
carry a significant risk of post-operative morbidity, liver dys-
function and mortality.5–7 These considerations are especially
relevant for patients with a compromised functional liver
reserve.
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A central hepatectomy (CH) was first reported for gallblad-
der cancer in 1972 and is used to describe the procedure to
resect segments 4, 5 and 8 (Fig. 1).8–14 The potential risks of
CH compared with traditional major liver resections such as
an extended- or hemi-hepatectomy include a longer operating
time, greater intra-operative blood loss and a higher risk of bil-
iary and vascular complications; all potentially attributed to
the presence of two parenchymal transection planes instead of
one. Another potential disadvantage of CH is compromise of
surgical margins. The potential advantages of CH include
preservation of liver parenchyma with the potential for
decreasing the risk of post-operative liver dysfunction or fail-
ure. A central hepatectomy may also increase the chance for a
future repeat resection.3,4,15–17
Recent reports, albeit few and small in sample size, have
demonstrated that CH is safe and is associated with compara-
ble complication and overall survival rates as compared with
conventional major hepatectomies.18 This current literature
comparing patients undergoing an extended hepatectomy (EH)
and CH consists of small retrospective studies largely involving
patients with hepatocellular carcinoma (HCC). These are
mostly Asian studies performed more than a decade ago and
their CH and EH cohorts are not matched (e.g. the CH cohort
in most of these studies was compared with a combined group
that included both lobar and extended hepatectomies and
patients’ clinicopathological factors were not comparable), thus
outcomes may not be fairly comparable as well.5,10,18 The aim
of this study was to analyse and compare the short- and long-
term outcomes for centrally located liver malignancies treated
with either CH or EH in matched cohorts.
Patients and methods
Patients undergoing liver resections at Memorial Sloan Ketter-
ing Cancer Center (MSKCC) were identified from a prospec-
tively maintained Hepatobiliary database between 1991 and
2013. Sixty-three patients comprised the cases (CH) and were
matched in a 1:1 ratio with EH controls selected from the lar-
ger group of patients who had undergone EH at the same per-
iod. Matching was initially performed with the following
variables: patient demographics [age at surgery (5 years),
body mass index (BMI) (< 25, 25–29, ≥30 kg/m2)], tumour
factors [disease diagnosis, tumour size (3 cm)] and pre-oper-
ative platelets count (50 9 109/l). These variables were
selected based on their known confounding effects on clinical
outcomes.19–21 The continuous matching criteria were widened
to age (10 years) and pre-operative platelets (100 9 109/l)
for 16 patients with CH in order to find an EH control; clini-
cally meaningful matching for tumor size was not possible for
these 16 patients. Finally, platelets count was further widened
in order to find controls for two cases. We performed the
comparison between the CH group and either a matched com-
bined EH group (patients who had undergone either right or
left EH) or a matched right EH group (patients who had
undergone right extended hepatectomy), as there were not
enough similarly matched patients for a separate cohort of
extended left hepatectomy patients. Wilcoxon’s matched-pairs
signed ranks test and exact McNemar’s test were used to exam-
ine the difference in covariates between the paired groups on
outcomes.
Patients’ demographics and clinicopathological variables
were analysed to compare short-term outcomes. Patients whose
tumours were either treated with a liver resection and intra-
operative ablation or patients who had undergone a prior liver
resection were excluded. Only patients with a confirmed patho-
logical diagnosis of malignancy were included. Cholangiocarci-
noma requiring bilio-enteric anastomosis was excluded given
the high risk of bile leak. All pathological specimens were
reviewed and confirmed by MSKCC pathologists. Definitions
and measurements of prognostic factors and clinical risk score
calculation (CLM patients only) were previously reported.22
Survival distributions were estimated from the date of surgery
using the Kaplan–Meier method (CLM patients only) and
compared with the stratified log-rank test. Overall survival
(OS) was defined as death from any cause. An event for
recurrence-free survival (RFS) was defined as either death or
Figure 1 Central hepatectomy–segment-orientated resection.14
Central segments labelled 4, 5, 8  1 (caudate lobe) are the
segments resected in a central hepatectomy (CH). The inflow
pedicles to segment 4 (A and B) are ligated and divided along the
umbilical fissure, the right anterior sectoral pedicle (C) is then
divided. The parenchymal transection proceeds from the left side
and then the right side until the two planes meet just anterior to
the inferior vena cava (IVC). The right hepatic vein (D) is preserved.
The middle hepatic vein (E) can be divided with a stapler.
Segments 4, 5, 8  1 are removed en masse. (Adapted from Liau,
et al.14)
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recurrence. Patients without events were censored at last fol-
low-up. All P-values were based on two-tailed statistical analy-
ses and P < 0.05 was considered to indicate statistical
significance. All analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA). Approval for the study was
obtained from the MSKCC institutional review board.
Pre-operative assessment
Complete staging and evaluation was performed prior to sur-
gery and included a history and physical examination, labora-
tory investigations and cross-sectional contrast-enhanced
imaging [computed tomography (CT) and/or Magnetic Reso-
nance Imaging (MRI)] of the chest, abdomen and pelvis (in-
cluding liver with liver-specific protocols). Other radiological
and diagnostic procedures were used at the discretion of the
treating physicians. Suitability for a liver resection and the type
of resection (CH or EH) was based on fitness for surgery, an
adequate future liver remnant (FLR) with adequate inflow, out-
flow and biliary drainage; and the likelihood to achieve an R0
resection with adequate margins. This decision is made by the
primary surgeon and discussed at a multidisciplinary conference
for radiological review, opinions and consensus if necessary.
Surgery
All liver resections were performed using a standard technique
as reported previously.23–25 Intra-operative ultrasonography was
routinely performed to detect additional tumours in the liver,
delineate the relationship of the tumour to major vascular and
biliary structures, as well as to guide the plane of parenchymal
transection. Similar to the Brisbane classification, a right EH
was defined as a liver resection of segments 5 to 8, if it included
a significant portion of segment 4 (with or without segment 1).
A left EH was defined as a liver resection of segments 2 to 4
and segment 8, if it included a significant portion of segment 5
or 8 (with or without segment 1).8 A central hepatectomy was
defined as a liver resection of segments 4, 5 and 8; procedures
were considered as CH in this study if the majority of segments
4a and 4b and the majority of segments 5 and 8 were removed,
with a significant bi-planar resection (Fig. 1).14,24,25
Post-operative morbidity and mortality were defined as
complications or deaths within 90 days after surgery, respec-
tively. Events were recorded prospectively in the department of
surgery complication database (MSKCC Surgical Secondary
Events Program) and graded in severity with a score of 1 to 5.
Grade 1 complications require only oral medication or bedside
medical care. Grade 2 events require intravenous medical ther-
apy, antibiotics or total parenteral nutrition with resolution.
Grade 3 events require radiological, endoscopic or operative
intervention. Grade 4 complications are associated with
chronic deficit or disability, and grade 5 is defined as mortality
associated with sequelae of the event.26
Post-hepatectomy liver failure (PHLF) was defined according
to a proposed consensus by the International Study Group of
Liver Surgery (ISGLS) in 2011.27 In essence, the ISGLS defined
PHLF as an increased INR and hyperbilirubinaemia (according
to the normal levels defined by the local laboratory) on or after
post-operative day (POD) 5. In addition, we also used the
‘50–50’ criteria as an alternative marker of liver dysfunction,
which is based on prothrombin time (PT) <50% and serum
bilirubin >3 mg/dl on POD 5.28
Results
Patients’ characteristics
A total of 4661 liver resections were performed at MSKCC
during the study period (1991 to 2013). After review of
operative details and diagnoses, 63 patients who had under-
gone CH were identified and another 886 patients who had
undergone EH were identified (724 right EH and 162 left
EH). The median age of patients who underwent CH was
61 years (range: 36–86) and the majority were being treated
for CLM (n = 44; 70%). After matching, the right EH group
included 63 patients, and the combined EH group included
11 left EH and 52 right EH patients. Table 1 details the
clinicopathological characteristics. No differences were noted
between the cases and controls with regard to the matching
criteria except for tumour size, which was 0.5 cm (median)
smaller in the CH group compared with the control groups
(P < 0.01 for both). Portal vein embolization (PVE) was not
performed in the CH group, whereas it was performed in
19% and 16% of the right EH and combined EH groups,
respectively.
Peri-operative outcomes
Shorter Pringle time and higher intra-operative blood loss were
observed in the right EH (P = 0.04 and P = 0.01, respectively)
and the combined EH group (P = 0.03 and P < 0.01, respec-
tively) compared with the CH group (Table 2). There was a
trend towards a lower 90-day morbidity in the CH group
(43%) compared with the right EH (59%, P = 0.1) and com-
bined EH groups (56%, P = 0.2). The length of hospital stay
was significantly longer in the control groups (P < 0.01 for
both). Compared with the CH group, the control groups
demonstrated significantly higher post-operative peak serum
total bilirubin (right EH versus CH: 3.2 versus 1.8 mg/dl,
P = 0.001; combined EH versus CH: 3 versus 1.8 mg/dl,
P = 0.001) and International Normalized Ratio (INR) levels
(right EH versus CH: 1.5 versus 1.3, P = 0.02; combined EH
versus CH: 1.5 versus 1.3, P = 0.02). A post-operative serum
bilirubin higher than 4 mg/dl was observed in 2% of the CH
group as compared with 39% in the right EH group (P < 0.01)
and 52% in the combined EH group (P < 0.01). The ‘50–50
criteria’ were not satisfied by any of the patients in any group.
In addition, no differences were noted with regard to the ISGLS
PHLF rates (CH: 62%, right EH: 74%, combined EH: 68%;
P = 1.0 for both) or 90-day mortality rates (CH: 1.6%, right
EH: 4.7%, combined EH: 4.7%; P = 0.6 for both). Symptomatic
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bile leak/biloma occurred in two patients (3%) in the CH
group, which resolved after percutaneous drainage. There were
no bile leaks/biloma in the EH groups (P = 0.5 for both).
Oncological outcome for patients with CLM
CLM was the most common diagnosis with 70% of the
patients in the cases and controls being treated for this diagno-
sis (44 patients in each group, Table 1). Among the patients
with CLM, no differences were noted in the R0 resection rates,
the actual margin width, or other prognostic factors between
the CH group and the EH groups (Table 2). The median OS
was shorter in the right EH group (35 months, P < 0.01) and
combined EH group (35 months, P = 0.04) compared with the
CH group (59 months). A similar trend was observed with the
median RFS in the CH group (17 months) compared with the
right EH group (14 months, P = 0.1) and the combined EH
groups (11 months, P = 0.07). The better OS in the CH group
may be explained in part by the non-statistical significant trend
towards smaller and more often solitary tumours in the CH
group although the Clinical risk score and other prognostic
factors such as nodal status of primary cancer and CEA levels
were comparable between the groups.
Surgical volume
In analysing our CH volume with respect to EH cases, three time
periods were analysed (1992–1998, 1999–2004 and 2005–2013).
There was a gradual increase in the number of CH performed
with 44% of all the CH being performed in the latest period
whereas the number of right EH performed decreased (Fig. 2).
The CH group and the EH groups did not differ in their 90-day
morbidity rates when stratified by time periods (Table 3).
Discussion
Surgical choices for centrally located liver tumours are limited.
The traditional right and left EH, which sacrifices the greater
part of the liver parenchyma, harbours substantial risks of
morbidity, liver failure and mortality.6 CH is an attractive pro-
cedure because it removes the tumour-bearing segments in
entirety while preserving the non-tumour liver.5,29 This is espe-
cially relevant for patients with limited functional liver reserve
such as those with cirrhosis or those with chemotherapy-asso-
ciated hepatotoxicity. However, CH can be more technically
challenging than the conventional EH. As a CH involves two
transection planes there is a need for preservation of the
Table 1 Patients’ and tumours’ characteristics stratified by cases (CH) and extended hepatectomy (EH) groups
CH group
(n = 63)
Right EH group
(n = 63)
P-valuea Combined
EH group (N = 63)
P-valueb
Demographics
Age at surgery, years 61 (36–86) 60 (35–81) 0.9 61 (31–81) 0.7
Male 44 (70%) 39 (62%) 0.4 40 (63%) 0.5
Body mass index, kg/mb
<25 15 (24%) 15 (24%) 1.0 15 (24%) 1.0
25–29 29 (46%) 29 (46%) 29 (46%)
≥30 19 (30%) 19 (30%) 19 (30%)
Tumour characteristics
Indication for surgery disease
Hepatocellular cancer 5 (8%) 5 (8%) 1.0 5 (8%) 1.0
Metastases – Colorectal 44 (70%) 44 (70%) 44 (70%)
Metastases – Others 14 (22%) 14 (22%) 14 (22%)
Largest tumour size, cm 3.6 (1–21) 4.1 (2–14) <0.01 4.1 (1–14) <0.01
Pre-operative investigations
Platelets, 9109/l 214 (95–453) 207 (112–467) 0.3 210 (112–467) 0.09
Creatinine, mg/dl 1.0 (0.6–1.6) 1.0 (0.6–1.7) 0.8 1.0 (0.6–1.90) 0.8
International Normalized Ratio 1.1 (0.9–1.7) 1.1 (0.9–1.7) 0.3 1.1 (0.88–1.67) 0.3
Bilirubin, mg/dl 0.6 (0.3–1.3) 0.7 (0.2–10.1) 0.3 0.6 (0.2–10.1) 0.4
Carcinoembryonic antigen, ng/ml
[CLM patients only (n = 44)]
13.7 (1.4–792) 12.3 (1.1–476) 0.9 20.6 (1.1–475.6) 0.9
Pre-operative portal vein embolization 0 12 (19%) <0.001 10 (16%) <0.01
CLM, colorectal liver metastasis; Continuous variables are expressed as median (range); categorical variables are expressed as n (%).
aComparison of the CH and right EH groups.
bComparison of the CH and combined EH groups.
Bold values denote P-values < 0.05.
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Table 2 Short- and long-term outcomes stratified by the cases (CH) and extended hepatectomy (EH) groups
CH group (n = 63) Right
EH group (n = 63)
P-valuea Combined
EH group (n = 63)
P-valueb
Operative details
Operative time, min 244 (110–539) 255 (112–557) 0.4 258 (5–557) 0.09
Blood loss, ml 500 (50–4500) 800 (100–5000) 0.01 850 (100–5000) <0.01
Total Pringle time, min 50 (0–136) 36 (0–151) 0.04 36 (0–151) 0.03
Resection status (CLM patients only)
R0 resection 34 (92%) 33 (89%) 0.7 32 (86.4%) 0.7
Margins width, mm 0.3 (0–2.4) 0.5 (0–3.5) 0.3 0.4 (0–3.5) 0.9
Morbidity and mortality
Length of stay, days 8 (5–42) 10 (5–62) <0.01 9 (5–62) <0.01
90-day mortality 1 (1.6%) 3 (4.7%) 0.6 3 (4.7%) 0.6
90-day morbidity 27 (43%) 37 (59%) 0.1 35 (56%) 0.2
Bile leak/biloma 2 (3%) 0 0.5 0 0.5
Major complications (≥Grade 3) 8 (19%) 8 (19%) 1.0 7 (17%) 0.7
Bilirubin, mg/dl
POD1 1.5 (0.6–3.9) 2.2 (0.6–7.6) <0.01 2 (0.4–7.6) <0.01
POD3 1.5 (0.6–3.8) 2.1 (0.4–13) <0.01 2 (0.4–13) 0.01
POD5 1.5 (0.5–3.0) 2.3 (0.4–14.9) <0.01 2.2 (0.4–14.9) 0.01
Maxc 1.8 (0.7–4.1) 3.2 (0.6–16.7) 0.001 3 (0.6–16.7) 0.001
Bilirubinc >4 mg/dl 1 (2%) 17 (39%) <0.01 12 (52%) <0.01
INR
POD1 1.2 (1.0–1.8) 1.4 (1.2–2.1) 0.17 1.4 (1.2–2.1) 0.1
POD3 1.2 (1.0–1.4) 1.3 (1.0–1.8) 0.16 1.3 (1.0–1.8) 0.04
POD5 1.1 (0.9–1.4) 1.3 (1.0–1.7) 0.2 1.2 (1.0–1.7) 0.02
Maxc 1.3 (1.1–1.8) 1.5 (1.2–6.0) 0.02 1.5 (1.2–6.0) 0.02
‘50–50’ criteria 0 0 NA 0 NA
ISGLS criteria (any grade) 13 (62%) 23 (74%) 1.0 23 (68%) 1.0
CH group
(n = 44)
Right EH group
(n = 44)
Combined EH group
(n = 44)
Oncological characteristics (CLM patients only)
Clinical risk score
0–2 31 (72%) 27 (61%) 0.3 25 (57%) 0.2
3–5 12 (27%) 17 (39%) 19 (43%)
Disease-free interval
<12 months 22 (55%) 19 (45%) 0.5 22 (53%) 1.0
>12 months 18 (45%) 23 (55%) 20 (48%)
Nodal status of the primary
Negative 17 (45%) 17 (40%) 0.8 13 (31%) 0.3
Positive 21 (55%) 25 (60%) 29 (69%)
Pre-operative CEA
<200 lg/l 33 (94%) 32 (87%) 0.7 33 (87%) 0.7
≥200 lg/l 2 (6%) 5 (13%) 5 (13%)
Tumor size
<5 cm 30 (73%) 28 (64%) 0.4 27 (61%) 0.8
≥5 cm 11 (27%) 16 (36%) 17 (39%)
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bilateral peripheral segments and its vasculature which can be
technically challenging especially in the presence of a large
and/or a deep-seated tumour in the central portion of the
liver. This study, which encompasses 23 years of experience at
Memorial Sloan Kettering Cancer Center, is the first matched
case-control comparison of CH and EH.
In the present study, the control groups were selected through
a comprehensive matching algorithm based on pre-operative
clinical characteristics pertaining to clinical outcomes. No dif-
ferences in baseline characteristics were observed between the
CH and the control EH groups, except for a minor and clini-
cally irrelevant (0.5 cm) difference in tumour size. However, a
trend was noted towards a lower 90-day morbidity rate in the
CH group, which was accompanied by a significantly lower
intra-operative blood loss and a shorter length of hospital stay.
Our findings are in line with the results reported by Qiu et al.30
who observed that CH was associated with lower morbidity
rates compared with non-matched EH cases.
For patients with liver disease considered for a major resec-
tion, pre-operative PVE is an option to induce hypertrophy of
Table 2 Continued
CH group
(n = 44)
Right EH group
(n = 44)
Combined EH group
(n = 44)
Solitary tumour
No 19 (46%) 29 (66%) 0.1 30 (68%) 0.06
Yes 22 (54%) 15 (34%) 14 (32%)
Median follow-upd 52 months 96 months NA 84 months NA
Median overall survival, months (95% CI) 59 (40–92) 35 (17–43) <0.01 35 (18–43) 0.04
Median recurrence-free survival, months (95% CI) 17 (14–30) 14 (9–25) 0.1 11 (8–26) 0.07
CLM, colorectal liver metastasis; Continuous variables are expressed as median (range); categorical variables are expressed as n (%); NA, not
analysed; POD, post-operative day. PT, prothrombin time; INR, International Normalized Ratio; CI, confidence interval; CEA, carcinoembryonic
antigen.
aComparison of the CH and right EH groups.
bComparison of the CH and combined EH groups.
cMax – maximal bilirubin or INR levels from post-operative day 1 through to day 7.
dFollow-up for survivors.
1992-1998 1999-2004 2005-2012
Central hepatectomy 17 18 28
Right EH 319 239 166
Left EH 69 34 59
0
50
100
150
200
250
300
350
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um
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nt
s
Central hepatectomy Right EH Left EH
Figure 2 Volume and period of surgery of the cases (CH) and extended hepatectomy (EH) groups
Table 3 90-day morbidity of the case (CH) and extended hepatectomy (EH) groups stratified by time periods
Time period CH group (n = 63) Right EH group (n = 63) P-value Combined EH group (n = 63) P-value
1992–1998 (n = 68) 11 (65%) 18 (72%) 0.7 16 (62%) 0.8
1999–2004 (n = 79) 9 (50%) 17 (53%) 1.0 15 (52%) 0.9
2005–2012 (n = 42) 7 (25%) 2 (33%) 0.6 4 (50%) 0.2
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the FLR in an effort to minimize the risk of PHLF, it also serves
as a dynamic test of the liver’s regeneration capacity.31–33
Ipsilateral PVE is a feasible pre-operative strategy facilitating
extended or staged resections. However, PVE is associated with
some risk of morbidity and livers with limited functional
reserve may have a lower than expected response to PVE.34
Thus, CH, as a parenchymal-preserving technique, may obviate
the need for PVE and avoid its associated morbidity. These
considerations are reflected by our findings that none of the
CH group patients had undergone pre-operative PVE, whereas
18% of the EH groups required a pre-operative PVE.
Post-hepatectomy liver failure is a major concern and a lead-
ing cause of morbidity and mortality in major liver resections
especially in patients with prior liver dysfunction (e.g. cirrhosis
in HCC patients or steatohepatitis in post-chemotherapy CLM
patients).31,33 The present study did not demonstrate mortality
differences between the matched groups of CH and EH
patients. However, differences were observed with markers of
liver dysfunction. Compared with the EH groups, the CH
group demonstrated significantly lower bilirubin levels
throughout the hospitalization and lower peak INR levels.
These data suggest that patients undergoing CH may be less
susceptible to liver dysfunction compared with EH.
As an observational and retrospective study, this analysis has
inherent selection limitations and the generalizability of these
results might be restricted to specialized high-volume centres.
However, this is the first matched study to compare CH and
EH groups with a separate subgroup analysis on resection for
CLM. The previous studies in the literature are mostly small
retrospective Asian single-centre studies performed more than
a decade ago, focusing mainly on HCC without a comparable
or matched control group, as the CH cohort in most of these
studies was compared to a combined group that included both
lobar and extended hepatectomies and patients’ clinicopatho-
logical factors were not comparable.5,10,18 This study is limited
by its modest sample size as CH was not previously a common
procedure in our practice. Admittedly, some but not all of
tumours in the EH control groups were likely amenable to
CH. Furthermore, the volumetric assessment was not per-
formed and, therefore, comparisons may have been biased.
This unique study design was enabled by the statistical power
of our prospectively maintained database that included 4661
liver resections. The matching algorithm reduced selection
factors and strengthened our findings. An additional exclusive
feature of the present study is the predominance of CLM in
our patients, as opposed to previous reports, which focused on
HCC patients.18
In conclusion, CH is safe and associated with a shorter hos-
pital stay and less post-operative liver dysfunction in a subset
of carefully selected patients. This approach does not seem to
compromise survival outcomes in patients with colorectal liver
metastases. CH should be considered in all patients with cen-
trally located tumours amenable to such a resection.
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